作者
Brian Diskin,Salma Adam,Marcelo Ferreira Cassini,Gustavo Sanchez,Miguel Liria,Berk Aykut,Chandan Buttar,Eric Li,Belen Sundberg,Ruben D. Salas,Ruonan Chen,Junjie Wang,Mirhee Kim,Mohammad Saad Farooq,Susanna Nguy,Carmine Fedele,Kwan Ho Tang,Ting Chen,Wei Wang,Mautin Hundeyin,Juan Andres Kochen Rossi,Emma Kurz,Muhammad Israr Ul Haq,Jason Karlen,Emma Kruger,Zennur Sekendiz,Dongling Wu,Sorin A. A. Shadaloey,Gillian Baptiste,Gregor Werba,Shanmugapriya Selvaraj,Cynthia A. Loomis,Kwok‐Kin Wong,Joshua Leinwand,George Miller
摘要
Programmed cell death protein 1 (PD-1) ligation delimits immunogenic responses in T cells. However, the consequences of programmed cell death 1 ligand 1 (PD-L1) ligation in T cells are uncertain. We found that T cell expression of PD-L1 in cancer was regulated by tumor antigen and sterile inflammatory cues. PD-L1+ T cells exerted tumor-promoting tolerance via three distinct mechanisms: (1) binding of PD-L1 induced STAT3-dependent 'back-signaling' in CD4+ T cells, which prevented activation, reduced TH1-polarization and directed TH17-differentiation. PD-L1 signaling also induced an anergic T-bet-IFN-γ- phenotype in CD8+ T cells and was equally suppressive compared to PD-1 signaling; (2) PD-L1+ T cells restrained effector T cells via the canonical PD-L1-PD-1 axis and were sufficient to accelerate tumorigenesis, even in the absence of endogenous PD-L1; (3) PD-L1+ T cells engaged PD-1+ macrophages, inducing an alternative M2-like program, which had crippling effects on adaptive antitumor immunity. Collectively, we demonstrate that PD-L1+ T cells have diverse tolerogenic effects on tumor immunity.